Avammune Therapeutics, along with its subsidiary Avammune Lifesciences, has raised $12 million (approximately ₹100 crore) in a Series A round co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I, managed by Kotak Alternate Asset Managers.
The round also saw participation from IvyCap Ventures and existing investor 1Crowd.
The funding will be used to accelerate the company’s proprietary pipeline focused on the innate immune system, develop orally bioavailable small molecules, and support the clinical advancement of its lead candidate, AVA-NP-695—an ENPP1 inhibitor.
Founded in 2020 by Arun B. Papaiah, Srinivasan Namala, and Aditya Kulkarni, Avammune is a biopharma startup discovering small molecule therapies targeting innate immunity to treat cancer and autoimmune disorders. Its pipeline addresses conditions including Osteosarcoma, Ewing’s Sarcoma, Triple-Negative Breast Cancer, GI cancers, and various autoimmune diseases.
AVA-NP-695 has demonstrated strong anti-tumor efficacy in multiple preclinical cancer models and in veterinary cancer patients under compassionate use.
Also Read | PayU Appoints Shailesh Paul as CEO of Wibmo
Another key candidate, AVA-ADR, is a potential first-in-class ADAR1 p150 inhibitor and among the few in the field to show in vivo efficacy.
With the global immuno-oncology market valued at $100 billion and growing at a 17% CAGR, Avammune aims to deliver impactful therapies by leveraging innovative science and targeting unmet needs in cancer treatment.
